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Peripheral neuropathy is characterized as a generalized, relatively homogeneous process aﬀecting many peripheral nerves and pre-
dominantlyaﬀectingdistalnerves.Theepidemiologyofperipheralneuropathyislimitedsincethediseasepresentswithvaryingeti-
ology,pathology,andseverity.Toxic,inﬂammatory,hereditary,andinfectiousfactorscancausedamagetotheperipheralnervesre-
sulting in peripheral neuropathy. Peripheral neuropathy is most commonly caused by diabetes, alcohol, HIV infection, and ma-
lignancy. We report a case of a 42-year-old female with 10-year history of progressively worsening peripheral neuropathy, hypothy-
roidism, and skin changes who presents with dyspnea secondary to recurrent pleural and pericardial eﬀusions. Prior to her arrival,
her peripheral neuropathy was believed to be secondary to chronic demyelinating inﬂammatory polyneuropathy (CDIP) given el-
evated protein in the cerebral spinal ﬂuid (CSF) which was treated with intravenous immunoglobulin (IVIG) and corticosteroids.
Unfortunately,herperipheralneuropathydidnothaveanyimprovement.Incidentally,patientwasfoundtohavesplenomegalyand
papilledema on physical exam. Serum protein electrophoresis showed a monoclonal pattern of IgA lambda. Patient met the di-
agnostic criteria for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. An un-
derlyingdiagnosisofPOEMSsyndromeshouldbeconsideredinpatientswithchronicdebilitatingneuropathyandanelevatedpro-
tein in the CSF.
1. Case Presentation
A42-year-oldSouthAsianfemalewithahistoryof10yearsof
disabling peripheral neuropathy treated with corticosteroids
and intravenous immunoglobulin (IVIG) without improve-
ment. About 1 year ago, she developed hypertrichosis, skin
hyperpigmentation, and nail clubbing and whitening (nail
clubbing, Figure 1; hypertrichosis and nail whitening,
Figure 2). She also developed hypothyroidism 1 year ago.
Evaluation of a headache 1 year ago revealed that the patient
had bilateral papilledema. Complete blood count showed a
white blood count of 7.8, hemoglobin of 10.4g/dL, hema-
tocrit of 31.9%, and platelets of 306. Cerebral spinal ﬂuid
analysis from a lumbar puncture showed a total protein of
63g/dL. Patient was presumed to have CDIP. Serum protein
electrophoresis showed a monoclonal pattern of IgA lambda.
She also began to have to functional decline and signiﬁcant
weight loss for the past 2 years. Computed tomography (CT)
of the chest showed pericardial eﬀusion and bilateral pleural
eﬀusions (Figure 3, arrows). For the past 3-4 months, she
developed dyspnea secondary to recurrent pleural eﬀusions
and pericardial eﬀusions requiring multiple thoracenteses
and pericardiocentesis, respectively. A CT Scan of the ab-
domen and pelvis conﬁrmed splenomegaly and ascites
(Figure 4, arrow). A whole body skeletal survey revealed
osteosclerotic lesions of the left iliac bone and proximal left
femur (Figure 5, arrow). By piecing together distinct signs
and symptoms, the most likely diagnosis is POEMS syn-
drome. There is no single laboratory test that can be per-
formed to diagnose POEMS syndrome. Multiple signs and
symptoms are associated together to establish the diagnosis
of POEMS syndrome. Two major criteria: polyneuropa-
thy and monoclonal plasmaproliferative disorder and at
least 1 minor criterion: osteosclerotic myeloma, Castle-
man’s disease, organomegaly, endocrinopathy (excluding
diabetes mellitus or hypothyroidism), edema, typical skin
changes, and papilledema are required for diagnosis of
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the Mayo Clinic [1]. The patient exhibits both major
criteria and many of the minor criteria (sclerotic bone
lesions, organomegaly, edema or eﬀusions, skin changes,
papilledema, and endocrinopathy).
2. Pathogenesis
The exact cause of POEMS syndrome is poorly understood,
althoughproinﬂammatorycytokineshavebeenimplicatedas
a cause of the disease [2–4]. Patients with POEMS syndrome
had higher serum levels of IL-1 beta, TNF-alpha, and IL-6
and lower serum levels of TGF beta 1 than did patients with
multiple myeloma [5]. Vascular endothelial growth factor
(VEGF) is a good pathogenic marker in POEMS [6, 7]; it
induces a rapid and reversible increase in vascular perme-
ability and neovascularization. The overproduction of VEGF
is important in the pathogenesis of POEMS syndrome.
Our patient had an Interleukin-6 level of 26.3pg/mL (0–
14pg/mL) and a VEGF level of 1960pg/mL (31–86pg/mL).
After chemotherapy and autologous stem cell transplanta-
tion, the symptoms of the syndrome improved along with
the decrease in serum VEGF levels [8, 9].
The median age of patients diagnosed with POEMS
syndrome is 51 years of age [1]. Peripheral neuropathy is
a signiﬁcant feature of the syndrome and a required criterion
for diagnosis. The peripheral neuropathy is ascending, with
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either an insidious or rapidly progressing onset. Patients
often initially have numbness and dysesthesias which is then
followed by a progressive ascending weakness that over-
shadows the sensory impairment. Increased cerebral spinal
ﬂuid protein was seen in all the patients from a case series.
Sixty-seven to eighty-four percent of patients will have an
endocrine abnormality at presentation with hypogonadism
being the most common and ﬁfty percent of the patients
had organomegaly (hepatomegaly, splenomegaly, and lym-
phadenopathy). Two-thirds of the patients had skin changes
(hyperpigmentation, hypertrichosis, acrocyanosis, plethora,
and hemangioma/telangiectasia).
A retrospective case series showed overall median sur-
vivalwas165months.Therehasnotbeenadocumentedcase
of POEMS syndrome in a South Asian American prior to
this case report. Previously, there were case series in Chinese
patients, Japanese patients, and non-Asians [10]. Prognos-
tic markers for survival included ﬁngernail clubbing and
e x t ra v a s c u l a rﬂ u i do v e r l o a d( e d e m a ,e ﬀusion, or ascites). Pa-
tients with clubbing or volume overload had a median sur-
vival of 31 and 79 months, respectively [1].
More than half the patients respond to radiation ther-
apy with nonneurologic manifestations improving prior to
neurologic manifestations. Patients with a solitary lesion or
a dominant lesion are treated with radiation therapy as ﬁrst-
line therapy. The hypothesis implicating vascular endothelial
growth factor [6–8] eventually may be validated, providing a
uniformtargetfortherapy.Systemicandskinsymptomstend
to respond sooner than do symptoms of peripheral neuropa-
thy, with the former beginning to respond within 1 month,
and the neuropathy responds within 3 to 6 months. Many
treatment strategies other than radiation therapy have been
used, including plasmapheresis, intravenous immunoglobu-
lin, interferon alfa, corticosteroids, alkylators, azathioprine,
autologous stem cell transplantation (ASCT), tamoxifen,
and transretinoic acid. The current mainstay treatment for
POEMS is radiation therapy and alkylator-based therapy
[11]. There have been promising results with the use of high-
dose chemotherapy with melphalan and autologous blood
stem cell transplantation.
3. Conclusion
There is vast spectrum of causes of peripheral neuropathy,
which commonly include diabetes, alcohol abuse, and HIV
infection. Our patient suﬀered from 10 years of chronic pe-
ripheral neuropathy, and she had an extensive workup by
multiple physicians. Ultimately, she was diagnosed with
POEMS syndrome, a rare paraneoplastic syndrome from a
plasma cell dyscrasia, which most commonly presents with
peripheral neuropathy. Although uncommon, POEMS syn-
drome should be considered among patients with chronic
peripheral neuropathy.
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